Type I Interferons in NeuroHIV

Viral Immunol. 2019 Jan/Feb;32(1):7-14. doi: 10.1089/vim.2018.0085. Epub 2018 Sep 27.

Abstract

Infection with Human Immunodeficiency Virus (HIV)-1 continues to cause HIV-associated neurocognitive disorders despite combined antiretroviral therapy. Interferons (IFNs) are important for any antiviral immune response, but the lasting production of IFNα causes exhaustive activation leading eventually to progression to AIDS. Expression of IFNα in the HIV-exposed central nervous system has been linked to cognitive impairment and inflammatory neuropathology. In contrast, IFNβ exerts anti-inflammatory effects, appears to control, at least temporarily, lentiviral infection in the brain and provides neuroprotection. The dichotomy of type I IFN effects on HIV-1 infection and the associated brain injury will be discussed in this review, because the underlying mechanisms require further investigation to allow harnessing these innate immune factors for therapeutic purposes.

Keywords: HIV-1; IFNα/β; NeuroAIDS; neurodegeneration; neuroprotection; type I interferon.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • AIDS Dementia Complex / immunology*
  • Animals
  • Antiviral Agents / therapeutic use
  • Brain / pathology
  • Brain / virology
  • Central Nervous System Viral Diseases / immunology*
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • Humans
  • Interferon Type I / immunology*
  • Interferon Type I / therapeutic use
  • Interferon-alpha / immunology
  • Interferon-alpha / therapeutic use
  • Interferon-beta / immunology
  • Interferon-beta / therapeutic use
  • Mice
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Interferon Type I
  • Interferon-alpha
  • Interferon-beta